CDK4 and breast carcinoma: While it is reasonable to consider using CDK4/6i beyond breast cancer, it turns out to be challenging because of (i) unsatisfactory efficacy, (ii) drug resistance, (iii) lack of reliable biomarkers for patient selection, and (iv) toxicity7–9.